Tagged with ARM

Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…

LatAm Diego Ocampo, Vice President of Technology at Neolpharma and President of the Mexican Foundation for Health Innovation (INCIDE), represents a new generation of pharmaceutical leadership combining global perspective with regional expertise. Having pursued graduate studies in medicinal chemistry at Tokyo University following his undergraduate work at UNAM, Ocampo has spent…

LatAm From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already considered global standards. According to the Waiting to Access Innovative Therapies (W.A.I.T.) Indicator from FIFARMA, an association representing research-based pharma…

UAE Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What matters now is execution, credibility, and the ability to move innovation through complex healthcare systems without losing focus. In this…

Brazil Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups. Billi discusses how operational discipline, long-term investment, and a strong global market mindset have underpinned Eurofarma’s sustained growth, while outlining…

France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…

Taiwan PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren Wang outlines how ONIVYDE® provides the stability to advance a more ambitious pipeline, how a virtual model sharpens scientific focus…

France Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a new phase of growth at the intersection of innovation, sovereignty and international ambition. In this conversation, recently appointed CEO Sébastien…

France ISISPHARMA’s story unfolds through the Dewavrin group’s evolution from textile manufacturing into a science driven portfolio spanning dermocosmetics and micronutrition. Grégoire Dewavrin explains how the brand has grown through a resolutely medical positioning, early international expansion and a strategy built on proximity to clinicians and local partners. As the organisation…

Brazil Brazil’s push to modernise its health system has put Interfarma at the centre of the region’s biggest access debate. Since taking over the presidency in 2023, Renato Porto has steered the association – which represents the innovative pharmaceutical industry in Brazil – through a period of regulatory reform, political uncertainty,…

LatAm Haig Yeghiaian, General Manager at LEO Pharma Brazil, brings extensive therapeutic area expertise spanning HIV, nephrology, and dermatology to his leadership of the company’s multifaceted Brazilian operations. Under his stewardship, LEO Pharma has evolved from a traditional retail-focused dermatology company into a diversified enterprise operating across six distinct market segments…